Table 1.
Basic information of the top enriched KEGG pathways.
| ID | Term | Enrichment | Pvalue | Count |
|---|---|---|---|---|
| hsa05417 | Lipid and atherosclerosis | 59.59 | 1.29482E-26 | 17 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 97.45 | 3.16262E-23 | 13 |
| hsa04932 | Non-alcoholic fatty liver disease | 67.51 | 1.15708E-22 | 14 |
| hsa05163 | Human cytomegalovirus infection | 50.25 | 2.64246E-22 | 15 |
| hsa05142 | Chagas disease | 88.21 | 6.37594E-21 | 12 |
| hsa04625 | C-type lectin receptor signaling pathway | 86.53 | 8.12367E-21 | 12 |
| hsa05161 | Hepatitis B | 60.38 | 2.07365E-20 | 13 |
| hsa05131 | Shigellosis | 39.37 | 5.96459E-18 | 13 |
| hsa05152 | Tuberculosis | 49.92 | 7.41814E-18 | 12 |
| hsa05135 | Yersinia infection | 60.35 | 2.42037E-17 | 11 |
| hsa04936 | Alcoholic liver disease | 57.83 | 3.91286E-17 | 11 |
| hsa04620 | Toll-like receptor signaling pathway | 69.46 | 1.85124E-16 | 10 |
| hsa04931 | Insulin resistance | 69.46 | 1.85124E-16 | 10 |
| hsa04668 | TNF signaling pathway | 63.62 | 4.57832E-16 | 10 |
| hsa05133 | Pertussis | 87.36 | 7.93439E-16 | 9 |
| hsa05140 | Leishmaniasis | 86.25 | 8.94626E-16 | 9 |
| hsa05415 | Diabetic cardiomyopathy | 40.62 | 2.03206E-15 | 11 |
| hsa05418 | Fluid shear stress and atherosclerosis | 53.70 | 2.60464E-15 | 10 |
| hsa04657 | IL-17 signaling pathway | 71.73 | 5.03257E-15 | 9 |
| hsa05171 | Coronavirus disease - COVID-19 | 34.99 | 1.29482E-26 | 17 |